Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on April 8, 2021. The filing discloses the entry into a material definitive agreement regarding a public offering of securities held by Harrow in another entity, Eton Pharmaceuticals, Inc.
Key Financial Metrics
The filing details a specific transaction rather than reporting Harrow's operational financials (revenue, profit, or cash flow). Key transaction metrics include:
- Shares Sold: 1,320,000 shares of Eton Pharmaceuticals, Inc. common stock (Firm Shares).
- Over-Allotment Option: Up to 198,000 additional shares exercisable within 45 days.
- Offering Price: $7.00 per share.
- Gross Proceeds to Harrow: Approximately $9.24 million (firm shares only) or approximately $10.63 million (if over-allotment is fully exercised).
- Net Proceeds: Not specified; gross proceeds are before underwriting discounts, commissions, and offering expenses.
- Proceeds to Eton: $0 (Eton receives no proceeds from this sale).
Material Changes
The primary material change is the reduction of Harrow's equity stake in Eton Pharmaceuticals, Inc. through the sale of 1,320,000 shares. The filing does not provide comparative financial data for Harrow's own operations versus prior periods.
Outlook, Risks, and Contingencies
- Closing Date: The transaction is expected to close on April 12, 2021, subject to customary closing conditions.
- Lock-Up Agreement: Harrow has agreed to a 180-day lock-up period following the agreement date, during which it cannot sell or dispose of additional Eton common stock or related securities without the Underwriter's consent.
- Underwriter: National Securities Corporation is acting as the sole book-running manager.
- Risk Factors: The filing notes that the description of the Underwriting Agreement is qualified by reference to the full document filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the final closing date of the transaction (expected April 12, 2021).
- Confirm whether the underwriter exercises the 198,000 share over-allotment option to determine total proceeds.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific underwriting discount rates and offering expenses to calculate net proceeds.
- Monitor Harrow's remaining equity position in Eton Pharmaceuticals post-transaction.